Neonatal disorders are often rare, and developing treatments for such conditions can be financially challenging. To address this, regulatory agencies offer [Orphan Drug Designation](), which provides incentives like tax credits, grant funding, and market exclusivity. This encourages pharmaceutical companies to invest in the development of treatments for rare neonatal disorders.
